How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Internet, Communication & Technology · Forecast 2027–2033
Pathology AI Software Market
- By Application: Cancer Diagnosis, Digital Pathology Image Analysis, Biomarker Detection, Tissue Segmentation, Quantitative Pathology
- By Product Type: Standalone Software, Integrated Software Solutions, Cloud-Based Platforms, On-Premise Software
- By End User: Hospitals and Clinics, Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes
- By Technology: Deep Learning Algorithms, Machine Learning Models, Image Recognition Technology, Natural Language Processing
- By Modality: Histopathology, Cytopathology, Molecular Pathology, Immunohistochemistry
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Cancer Diagnosis leads By Application at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.186 →
Full report · locked preview
Everything inside the Pathology AI Software Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Application 5
Product Type 4
End User 4
Technology 4
Modality 4
Companies profiled
Philips Healthcare
Roche Diagnostics
Paige.AI
PathAI
Ibex Medical Analytics
Proscia
Huron Digital Pathology
Inspirata
Visiopharm
ContextVision
Aiforia Technologies
DeepLens
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Philips Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Paige.AI
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →PathAI
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Ibex Medical Analytics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Proscia
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Huron Digital Pathology
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Inspirata
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Visiopharm
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →ContextVision
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Aiforia Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →DeepLens
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →OptraSCAN
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Indica Labs
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Prognos Health
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,008M by 2033 · 11.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Cancer Diagnosis48.7
- Digital Pathology Image Analysis13.3
- Biomarker Detection12.2
- Tissue Segmentation16.1
- Quantitative Pathology9.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$843.4M → $1,961M · 11.1%
Europe$587.8M → $1,454M · 12.0%
Asia Pacific$536.7M → $1,397M · 12.7%
Latin America$332.2M → $792.4M · 11.5%
Middle East and Africa$255.6M → $650.9M · 12.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.232026
11.242027
11.252028
11.272029
11.282030
11.292031
11.302032
11.312033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Philips Healthcare12.4
- Roche Diagnostics23.2
- Paige.AI5.7
- PathAI10.4
- Ibex Medical Analytics11.3
- Proscia9.1
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Application12.9%
Product Type23.0%
End User31.3%
Technology16.8%
Modality16.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.4
- Europe23.2
- Asia Pacific22.3
- Latin America12.7
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Philips Healthcare | 89 | 88 | 75 | 99 | 97 | 92 | 90 |
| Roche Diagnostics | 75 | 86 | 83 | 91 | 81 | 85 | 84 |
| Paige.AI | 74 | 84 | 83 | 64 | 88 | 65 | 76 |
| PathAI | 77 | 59 | 57 | 64 | 64 | 67 | 65 |
| Ibex Medical Analytics | 55 | 71 | 53 | 72 | 52 | 56 | 60 |
| Proscia | 51 | 50 | 50 | 50 | 62 | 61 | 54 |
| Huron Digital Pathology | 64 | 45 | 61 | 48 | 62 | 59 | 57 |
| Inspirata | 38 | 44 | 42 | 40 | 44 | 48 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Philips Healthcare
- Roche Diagnostics
- Paige.AI
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Philips Healthcare | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Roche Diagnostics | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Paige.AI | ◐ | ◐ | ◐ | − | ✓ | ◐ |
| PathAI | ✓ | ◐ | − | ◐ | − | ✓ |
| Ibex Medical Analytics | − | ◐ | ◐ | ◐ | − | − |
| Proscia | − | − | ◐ | ◐ | − | ◐ |
| Huron Digital Pathology | − | − | ◐ | − | ◐ | ◐ |
| Inspirata | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Philips Healthcare90
2Roche Diagnostics84
3Paige.AI76
4PathAI65
5Ibex Medical Analytics60
6Huron Digital Pathology57
7Proscia54
8Inspirata43
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Philips HealthcareRoche Diagnostics
Challenger1
Strong scale, closing on the leaders.
Paige.AI
Contender3
Focused players with pockets of strength.
PathAIIbex Medical AnalyticsHuron Digital Pathology
Niche2
Specialists in a single segment or region.
ProsciaInspirata
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Application in North America, then scale across Pathology AI Software Market — a $171M beachhead inside a $2.39B market.
Beachhead (SOM)$171Mobtainable near-term
Serviceable (SAM)$929Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Cancer Diagnosis
Best fit — highest urgency & budget in Application.
Economic buyer79 fit
Digital Pathology Image Analysis
Strong fit — clear ROI and a fast path to value.
End user66 fit
Biomarker Detection
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Application in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Product Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel28%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Application leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Pathology AI Software Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified22%
Evaluation13%
Closed-won5%
$8.3KCAC
$40KLTV
4.8:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Pathology AI Software Market is a high-growth opportunity — $7.14B by 2033, compounding at 10.7%.
TAM · 2025$3.17Btoday
TAM · 2033$7.14Bforecast
CAGR10.7%2027–2033
Cumulative$44.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.14BTotal addressable market
SAM$2.61BServiceable available market
SOM$427MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.7% CAGR
Demand compounds through 2033, outpacing GDP across Application.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Application moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.14BLarge & growingTAM by 2033 at 10.7% CAGR
$2.61BServiceable nowreachable with today’s model
$427MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.57BBear6.9% CAGR
$7.14BBase10.7% CAGR
$9.14BBull14.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Product Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Pathology AI Software Market — a $1.09B market by 2033. Plan: grow share from 9.4% to 18.1%.
Market size · 2033$1.09Btotal addressable
Market CAGR8.1%2027–2033
Target share18.1%from 9.4% today
Revenue ambition$198Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.4% | 18.1% | On track |
| Revenue | $99M | $198M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 29.0% | 45.3% | On track |
| Customer retention | 91.6% | 96.3% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Application
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Product Type capability
A defensible second engine — invest in Product Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Application share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Product Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $29M capacity & capability investment
- Greenlight bolt-on M&A in Product Type
- Authorise North America expansion plan
- Fund R&D program for Application leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Pathology AI Software Market conversation — a $9.50B market you can size, segment and defend in minutes.
Market size · 2033$9.50Btotal opportunity
Growth7.9%CAGR to 2033
Addressable buyers1,577+accounts in scope
Typical ROI4.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Application
Goal Grow share in Application
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.9×return on cost, year one
< 3 mopayback period
$75K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Philips HealthcareRoche DiagnosticsPaige.AIPathAIIbex Medical AnalyticsProsciaHuron Digital PathologyInspirata+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Pathology AI Software Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Pathology AI Software Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Internet, Communication & Technology · scroll →Data Governance Practice Platform Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportBig Data User Behavior Analysis Platform Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportIndustrial Metaverse Solution Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportSpace Weather Data Service Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportMulti-Layered AI Security Solution Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportVector Database Solution Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportLive Broadcast Full Case Planning Service Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportHyperconverged Database Software Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportKnowledge Open Source Platform Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportEducational Publishing Technology Service Market
Educational Publishing Technology Service Market is valued at USD 11.45 Billion in 2025 and is …
$11.5B market · 2025 base year
View reportBig Data Anti-Fraud Service Market
Market size, share, segmentation and regional forecast.
$554M market · 2025 base year
View reportAI Music Generation Service Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.